Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

• Results Overview

  Dupilumab treatment improved eczema symptoms and skin health at the cellular level, while being well-tolerated by patients. The drug worked by reducing inflammation and improving skin barrier function over a 16-week period.

• Study Summary

  Num Participants:

  54

  Study Type:

  Rct

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  {'Transcriptome improvement week 4': 68.8, 'Transcriptome improvement week 16': 110.8}

  Efficacy End Points Control:

  {'Transcriptome improvement week 4': -10.5, 'Transcriptome improvement week 16': 55.0}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected